August 11, 2015
A New York federal judge awarded $60 million in attorneys' fees Tuesday to Robbins Geller Rudman & Dowd LLP, lead counsel in a shareholder class action accusing Pfizer Inc. of misleading investors about off-label marketing of various drugs, less than two-thirds of the $94 million the firm had asked for.
July 31, 2015
A New York federal judge on Thursday granted final approval of a $400 million settlement that ends a class action accusing Pfizer Inc. of misleading investors about illegal off-label drug marketing, though some investors may not get much with a recovery rate of 15 cents per share.
June 08, 2015
Plaintiffs pushing for final approval of a $400 million settlement with Pfizer Inc. in an off-label marketing class action urged a New York federal judge on Friday to overrule objections to a $94 million fee request by lead counsel from Robbins Geller Rudman & Dowd LLP.
May 19, 2015
Robbins Geller Rudman & Dowd LLP is getting greedy with its $94 million fee request in a $400 million settlement with Pfizer Inc., one of the investor plaintiffs complained to a New York federal judge Monday.
May 06, 2015
Robbins Geller Rudman & Dowd LLP, lead counsel in a shareholder class action accusing Pfizer Inc. of misleading investors about the off-label marketing of various drugs, asked a New York federal judge on Wednesday to approve $94 million in attorneys' fees to be paid out of the $400 million settlement.
March 16, 2015
A New York federal judge on Monday granted early approval to a $400 million settlement ending a class action lawsuit accusing Pfizer Inc. of misleading investors about illegal off-label drug marketing, after attorneys revised notices to class members clarifying details about the litigation.
February 26, 2015
A proposed $400 million deal to resolve a class action lawsuit accusing Pfizer Inc. of misleading investors about illegal off-label drug marketing was put on track for approval on Thursday, but not before a Manhattan federal judge asked pointed questions about the value of the deal and demanded a fresh round of opt-out notices for investors.
January 27, 2015
Pfizer Inc. has reached a $400 million settlement to avoid an upcoming trial in a class action claiming the company misled investors about an alleged off-label drug marketing scheme, the pharmaceutical giant said Tuesday in a regulatory filing.
October 30, 2014
A former Pfizer Inc. sales manager who was convicted in 2009 for illegal drug marketing can't be forced to testify in a class action suit alleging the pharmaceutical giant concealed a broader fraud scheme from investors, a New York federal judge ruled Thursday.
November 29, 2011
A New York federal judge on Tuesday ordered Pfizer Inc. to turn over about 32 million pages of documents to class action lawyers who claim the company broke securities laws by hiding illegal off-label drug marketing.